THE WOODLANDS, Texas and HUMMELSTOWN, Pa., March 17, 2026 /PRNewswire/ -- Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), today announced a ...

Eveo Cell Therapy Platform enables automated, multi-parallel intensified production of autologous cell therapies Compact design can increase output up to fourfold in existing cleanroom space 90 ...

Shares of ImmunityBio IBRX rose more than 7% on Friday after the company announced that it completed two manufacturing ...

Pharmaceutical companies are shifting from the development of autologous cell therapies to allogeneic cell therapies.

ImmunityBio (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced the successful completion of manufacturing engineering programs, NK2022 and NK2023, establishing a safe, ...

Cell therapy, one of the most promising frontiers in modern medicine, holds the potential to cure once-incurable diseases such as cancer and genetic disorders. But for all its promise, manufacturing ...

Trenchant BioSystems and Invetech agreed to collaborate on the continued development of Trenchant’s fully automated AutoCell Platform, intended for future commercialization. According to company ...

The first half of 2025 has been a notable one for Cellares. The cell therapy manufacturer operates its first commercial-scale Integrated Development and Manufacturing Organization Smart Factory in ...

The AMT designation gives Cellares’ clients using the Cell Shuttle priority review with the FDA leading to accelerated regulatory filings SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cellares, the ...

The "Cell and Gene Therapy Manufacturing Market -- Growth, Share, Opportunities & Competitive Analysis, 2024 -- 2032" report has been added to the Credence Research Inc. offering. The global Cell and ...

NeuroScientific Biopharmaceuticals has begun transferring the production of stem cells for its StemSmart therapy to Q-Gen in Brisbane, ahead of Crohn’s disease clinical trials.